Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Esther Rajavelu
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 25
- Beta
- 1.48
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- -5.35
Financials
Revenue
$0.00-100.0%Net Income
$-9.55MEBITDA
$-9.55MFree Cash Flow
$-5.36MEPS (diluted)
$-0.16Shares Outstanding (diluted)
57.97M+777.7%Operating Expenses
$9.93MCash & Debt
$50.77MReturn of Capital
$0.00Revenue by Segment (annual)
$66.80MDividend per Share
$0.01Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $59.62M | $8.57M | $0.15 |
| 2024 | $47.98M | $-68.57M | $-1.27 |
| 2023 | $103.78M | $22.81M | $0.43 |
| 2022 | $48.58M | $-46.41M | $-1.23 |
| 2021 | $3.07M | $-89.76M | $-2.91 |
| 2020 | $9.33M | $-78.28M | $-3.52 |
| 2019 | $18.15M | $-60.92M | $-3.31 |
| 2018 | $3.97M | $-41.66M | $-2.60 |
| 2017 | $1.98M | $-46.10M | $-17.82 |
| 2016 | $335.0K | $-25.49M | $-3.86 |
| 2015 | $0.00 | $-10.15M | $-1.54 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.22
- Implied price
- $3.60
- Return from $1.19
- 24.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1.79 — today's price is already 33.5% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| -2.0% | 6.9% | 10.2% | 13.2% | 15.9% | 18.4% |
| 3.0% | 12.3% | 15.9% | 19.0% | 21.8% | 24.4% |
| 8.0% | 17.8% | 21.5% | 24.8% | 27.7% | 30.5% |
| 13.0% | 23.2% | 27.1% | 30.5% | 33.7% | 36.5% |
| 18.0% | 28.7% | 32.7% | 36.3% | 39.6% | 42.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
107Social Signal Score
Mentions (3)
- Newsseekingalpha.com·54d ago·Positive
Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·54d ago·Neutral
Spero Therapeutics Q2 Earnings Call Highlights Spero Therapeutics NASDAQ: SPRO used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for SP001, an antibody candidate the company plans to develop initially for IgG4-related disease.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.14 per share
Typical surprise +48.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.16 vs $-0.17beat
- Wed, May 13$-0.13 vs $-0.18beat
- Thu, Mar 26$0.53 vs $-0.20beat
- Thu, Nov 13$-0.13 vs $-0.25beat
- Tue, Aug 12$-0.03 vs $-0.38beat
- Tue, May 13$-0.25 vs $-0.55beat
Estimates and results for SPRO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SPRO officers and directors.
- Bought
- —
- Sold
- $1.3m
0 trades
39 trades
- Rajavelu Esthersold
- Rajavelu Esthersold
- Rajavelu Esthersold
- Keutzer Timothysold
- Keutzer Timothysold
- Keutzer Timothysold
- Keutzer Timothysold
- Rajavelu Esthersold
61 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SPRO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.